Federica Furfaro

List of Publications by Year
in descending order

94 papers	3,003 citations	218677 26 h-index	182427 51 g-index
94 all docs	94 docs citations	94 times ranked	3395 citing authors

#	Article	IF	Citations
1	Early Biological Therapy in Operated Crohnâ€™s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflammatory Bowel Diseases, 2023, 29, 539-547.	1.9	6
2	Predictive Value of Bowel Ultrasound in Crohnâ€™s Disease: A 12-Month Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, e723-e740.	4.4	30
3	Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 446-454.	3.7	21
4	Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. Journal of Clinical Medicine, 2022, 11, 569.	2.4	3
5	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. Journal of Clinical Medicine, 2022, 11, 509.	2.4	1
6	Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. Journal of Clinical Medicine, 2022, 11, 353.	2.4	3
7	Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 872.	2.4	3
8	JAK inhibitors in crohnâ€™s disease: ready to go?. Expert Opinion on Investigational Drugs, 2022, 31, 145-161.	4.1	2
9	Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. Journal of Clinical Medicine, 2022, 11, 939.	2.4	20
10	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterology Journal, 2022, 10, 190-197.	3.8	11
11	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.9	22
12	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. Biomedicines, 2022, 10, 843.	3.2	6
13	Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual) Tj ETQq1 1 0.784314 rgBT /Ove lo multicenter international study (with video). Gastrointestinal Endoscopy, 2022, 96, 73-83.	1.0	8
14	Point-of-Care Ultrasound in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 143-151.	1.3	46
15	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterology Journal, 2021, 9, 438-442.	3.8	34
16	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. Digestive and Liver Disease, 2021, 53, 712-716.	0.9	6
17	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. Current Drug Targets, 2021, 22, 347-355.	2.1	7
18	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. Current Drug Targets, 2021, 22, 370-378.	2.1	1

#	Article	IF	Citations
19	TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. Current Drug Targets, 2021, 22, 760-769.	2.1	11
20	Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. Life, 2021, 11, 649.	2.4	5
21	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World Journal of Gastroenterology, 2021, 27, 4276-4297.	3.3	13
22	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110056.	3.2	11
23	Psychological Challenges for Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. Psychosomatic Medicine, 2021, 83, 397-398.	2.0	0
24	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22.	1.3	741
25	ECCO Guidelines on Therapeutics in Crohnâ€™s Disease: Surgical Treatment. Journal of Crohn's and Colitis, 2020, 14, 155-168.	1.3	478
26	Validation of the Red Flags Index for Early Diagnosis of Crohnâ€™s Disease: A Prospective Observational IG-IBD Study Among General Practitioners. Journal of Crohn's and Colitis, 2020, 14, 1777-1779.	1.3	18
27	Endoscopy after surgery in inflammatory bowel disease: Crohnâ€™s disease recurrence and pouch surveillance. Expert Review of Gastroenterology and Hepatology, 2020, 14, 829-841.	3.0	4
28	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. American Journal of Gastroenterology, 2020, 115, 1719-1721.	0.4	4
29	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clinical Gastroenterology and Hepatology, 2020, 18, 2134-2135.	4.4	101
30	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 507-516.	17.8	16
31	Targeting the gut layers in Crohnâ€™s disease: mucosal or transmural healing?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 775-787.	3.0	13
32	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology and Hepatology, 2020, 14, 797-806.	3.0	15
33	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 819-828.	3.0	2
34	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. Journal of Crohn's and Colitis, 2020, 14, 1330-1333.	1.3	69
35	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opinion on Biological Therapy, 2020, 20, 421-427.	3.1	15
36	Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 413-420.	3.1	24

#	Article	IF	Citations
37	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2020, 18, 1882-1883.	4.4	40
38	Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 203-213.	0.9	13
39	Patientâ€™s profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Review of Gastroenterology and Hepatology, 2020, 14, 765-773.	3.0	11
40	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. Current Pharmaceutical Design, 2019, 25, 25-31.	1.9	9
41	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflammatory Bowel Diseases, 2019, 25, 1399-1407.	1.9	27
42	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohnâ€™s disease. Digestive and Liver Disease, 2019, 51, 804-811.	0.9	3
43	Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Review of Gastroenterology and Hepatology, 2019, 13, 547-555.	3.0	4
44	Psychological Functioning of Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, e112-e112.	1.9	1
45	Late-onset Crohnâ€™s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€˜AGEDâ€™ study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	1.6	14
46	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. Gut, 2019, 68, 562-572.	12.1	42
47	Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opinion on Biological Therapy, 2019, 19, 1023-1030.	3.1	20
48	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Digestive and Liver Disease, 2019, 51, 510-515.	0.9	18
49	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 417-423.	1.3	35
50	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes, 2019, 10, 149-158.	9.8	70
51	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. Current Pharmaceutical Design, 2019, 25, 7-12.	1.9	8
52	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. Current Drug Targets, 2019, 20, 1327-1338.	2.1	3
53	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 601-606.	1.9	50
54	Validation of the â€˜United Registries for Clinical Assessment and Researchâ€™ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	1.3	8

#	Article	IF	Citations
55	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. European Journal of Gastroenterology and Hepatology, 2018, 30, 316-322.	1.6	30
56	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. Journal of Crohn's and Colitis, 2018, 12, S678-S686.	1.3	64
57	JAK inhibitors: Novel developments in management of ulcerative colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 89-93.	2.4	17
58	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2018, 27, 595-599.	4.1	57
59	Can IL-23 be a good target for ulcerative colitis?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 95-102.	2.4	31
60	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohnâ€™s Disease and Guiding Clinical Decision-making. Journal of Crohn's and Colitis, 2018, 12, 1280-1287.	1.3	79
61	PF-00547659 for the treatment of Crohnâ€™s disease and ulcerative colitis. Expert Opinion on Investigational Drugs, 2018, 27, 623-629.	4.1	4
62	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. Journal of Crohn's and Colitis, 2018, 12, 1385-1391.	1.3	85
63	IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. Expert Review of Clinical Immunology, 2017, 13, 457-467.	3.0	16
64	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opinion on Drug Safety, 2017, 16, 437-443.	2.4	24
65	Efficacy of tumour necrosis factor antagonists in stricturing Crohnâ€™s disease: A tertiary center real-life experience. Digestive and Liver Disease, 2017, 49, 872-877.	0.9	33
66	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion, 2017, 96, 166-172.	2.3	15
67	Rapid Detection of Anti-Infliximab Antibodies in Inflammatory Bowel Disease Patients Treated with the Reference Biologic or the Biosimilar CT-P13: Performance Comparison with Elisa. Gastroenterology, 2017, 152, S384.	1.3	0
68	Switching from Infliximab Originator to CT-P13 is not Related to Increased Immunogenicity in IBD Patients: A Prospective Case-Control Study. Gastroenterology, 2017, 152, S384.	1.3	0
69	Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S386.	1.3	0
70	Comparative Accuracy of us Versus MRI and Colonoscopy in Assessing Disease Activity and Complications and Influencing the Decision-Making Process in Crohn's Disease. Gastroenterology, 2017, 152, S66.	1.3	0
71	Stimulation of CYP450-Mediated ÃŽÂ©-3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S188.	1.3	0
72	Illness Perception in IBD Patients: A Prospective Study. Gastroenterology, 2017, 152, S800.	1.3	0

#	Article	IF	Citations
73	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisÂinÂMice. Gastroenterology, 2017, 153, 1363-1377.e6.	1.3	48
74	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. Liver International, 2017, 37, 141-147.	3.9	1
75	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD â€œAGED studyâ€. Digestive and Liver Disease, 2017, 49, 17-23.	0.9	35
76	Letter: immunogenicity of infliximab originator vs. <scp>CT</scp>â€Ƥ13 in <scp>IBD</scp> patients. Alimentary Pharmacology and Therapeutics, 2017, 46, 903-905.	3.7	7
77	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterology, 2017, 63, 319-326.	0.5	1
78	Unrevealed Depression Involves Dysfunctional Coping Strategies in Crohnâ€™s Disease Patients in Clinical Remission. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	9
79	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. Gastroenterology, 2016, 150, S6.	1.3	0
80	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2016, 14, 1426-1432.e1.	4.4	39
81	Mo1987 Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps. Gastrointestinal Endoscopy, 2016, 83, AB485.	1.0	0
82	Emerging therapeutic targets and strategies in Crohnâ€™s disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 735-744.	3.0	6
83	Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An InÂVivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters. Ultrasound in Medicine and Biology, 2016, 42, 150-158.	1.5	9
84	The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. Digestive and Liver Disease, 2015, 47, 646-651.	0.9	19
85	Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus. HIV/AIDS - Research and Palliative Care, 2014, 6, 69.	0.8	5
86	Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World Journal of Gastroenterology, 2014, 20, 3507.	3.3	35
87	Perianal disease is associated with psychiatric co-morbidity in Crohnâ€™s disease in remission. International Journal of Colorectal Disease, 2014, 29, 1285-1290.	2.2	36
88	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1146-1151.	1.6	26
89	Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2014, 15, 1659-1670.	1.8	14
90	Assessment of the disease extension in children and adolescents with IBD: Comparison of bowel ultrasound and magnetic resonance enterography. Digestive and Liver Disease, 2014, 46, e120.	0.9	1

#	Article	IF	Citations
91	The Importance of Disease Prevalence in Assessing the Diagnostic Value of a Test: Endoscopic Markers in Celiac Disease. Digestion, 2013, 87, 254-261.	2.3	8
92	Transperineal Perineal Ultrasound Versus Magnetic Resonance Imaging In the Assessment of Perianal CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2013, 19, 2737-2743.	1.9	55
93	Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up. Journal of Crohn's and Colitis, 2012, 6, 588-596.	1.3	48
94	Response Evaluation and Safety of Thiopurines in the Treatment of Inflammatory Bowel Diseases (IBD). Gastroenterology, 2011, 140, S-280-S-281.	1.3	0